World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
88
Citations
52073
World Ranking
12897
National Ranking
692

Nikolaus Marx publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Nikolaus Marx sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 736 publications — 83rd percentile

83% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Nikolaus Marx D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Nikolaus Marx sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 88 D-Index — 36th percentile

36% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Nikolaus Marx is affiliated with RWTH Aachen University in Germany and has a significant body of research primarily in the medical field. Their work focuses extensively on endocrinology, diabetes, and metabolism, as well as cardiology and cardiovascular medicine, with additional contributions in surgery, molecular biology, and pulmonary and respiratory medicine.

Their research covers several core topics, including diabetes treatment and management, diabetes management and research, cardiovascular function and risk factors, lipoproteins and cardiovascular health, metabolism related to diabetes and cancer, heart failure treatment and management, and the interplay between diabetes, cardiovascular risks, and lipoproteins.

Recent papers that feature their research contributions include:

  • "Empagliflozin in Heart Failure with a Preserved Ejection Fraction" (2021), published in New England Journal of Medicine
  • "Cardiovascular Disease in Chronic Kidney Disease" (2021), published in Circulation
  • "2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)" (2024), published in European Heart Journal
  • "2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes" (2023), published in European Heart Journal
  • "Swarm Learning for decentralized and confidential clinical machine learning" (2021), published in Nature

Among frequent coauthors collaborating with Nikolaus Marx are Dirk Müller-Wieland, Michael Lehrke, Katharina Schütt, Michael Dreher, and Andreas L. Birkenfeld.

Their research is commonly disseminated in key scientific venues such as the European Heart Journal, Diabetologie und Stoffwechsel, Journal of Clinical Medicine, Diabetes, and Circulation. Nikolaus Marx has published 39 works in the European Heart Journal, 16 in Diabetologie und Stoffwechsel, and 14 in the Journal of Clinical Medicine, among others.

The primary field of study for this scientist is medicine, with 919 publications linked to this domain. Their subfields of study emphasize areas including endocrinology, diabetes, and metabolism, as well as cardiology and cardiovascular medicine, reflecting a multidisciplinary approach to health sciences research.

Best Publications

  • 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology.

    Gilles Montalescot;Udo Sechtem;Stephan Achenbach;Felicita Andreotti

  • 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD

    Francesco Cosentino;Peter J Grant;Victor Aboyans;Clifford J Bailey

  • Empagliflozin in heart failure with a preserved ejection fraction

    Stefan D Anker;Javed Butler;Gerasimos Filippatos;João P Ferreira

  • PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties.

    M. Amine Bouhlel;M. Amine Bouhlel;M. Amine Bouhlel;Bruno Derudas;Bruno Derudas;Bruno Derudas;Elena Rigamonti;Elena Rigamonti;Elena Rigamonti;Rébecca Dièvart;Rébecca Dièvart;Rébecca Dièvart

  • Cardiovascular Disease in Chronic Kidney Disease: Pathophysiological Insights and Therapeutic Options.

    Joachim Jankowski;Jürgen Floege;Danilo Fliser;Michael Böhm

  • ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - summary.

    pre-diabetes Task Force on diabetes;Lars Rydén

  • Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.

    Julio Rosenstock;Vlado Perkovic;Odd Erik Johansen;Mark E. Cooper

  • T-lymphocyte infiltration in visceral adipose tissue: a primary event in adipose tissue inflammation and the development of obesity-mediated insulin resistance.

    Ulrich Kintscher;Martin Hartge;Katharina Hess;Anna Foryst-Ludwig

  • Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association.

    Sarah D. de Ferranti;Ian H. de Boer;Vivian Fonseca;Caroline S. Fox

  • PPARα Activators Inhibit Cytokine-Induced Vascular Cell Adhesion Molecule-1 Expression in Human Endothelial Cells

    Nikolaus Marx;Galina K. Sukhova;Tucker Collins;Peter Libby

  • Macrophages in Human Atheroma Contain PPARγ: Differentiation-Dependent Peroxisomal Proliferator-Activated Receptor γ (PPARγ) Expression and Reduction of MMP-9 Activity through PPARγ Activation in Mononuclear Phagocytes in Vitro

    Nikolaus Marx;Galina Sukhova;Curran Murphy;Peter Libby

  • Peroxisome Proliferator-Activated Receptors and Atherogenesis: Regulators of Gene Expression in Vascular Cells

    Nikolaus Marx;Hélène Duez;Jean-Charles Fruchart;Bart Staels

  • ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. The Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD)

    Lars Rydén;Peter J. Grant;Stefan D. Anker;Christian Berne

  • The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia.

    Jean-Charles Fruchart;Frank Sacks;Michel P Hermans;Gerd Assmann

  • Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial.

    Julio Rosenstock;Steven E. Kahn;Odd Erik Johansen;Bernard Zinman;Bernard Zinman

  • PPARγ Activation in Human Endothelial Cells Increases Plasminogen Activator Inhibitor Type-1 Expression PPARγ as a Potential Mediator in Vascular Disease

    Nikolaus Marx;Todd Bourcier;Galina K. Sukhova;Peter Libby

  • PPAR Activators as Antiinflammatory Mediators in Human T Lymphocytes Implications for Atherosclerosis and Transplantation-Associated Arteriosclerosis

    Nikolaus Marx;Bettina Kehrle;Klaus Kohlhammer;Miriam Grüb

  • Peroxisome Proliferator-Activated Receptor-γ Activators Inhibit IFN-γ-Induced Expression of the T Cell-Active CXC Chemokines IP-10, Mig, and I-TAC in Human Endothelial Cells

    Nikolaus Marx;François Mach;Alain Sauty;Josephine H. Leung

  • Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control : Results from the pioneer study

    Andreas Pfützner;Nikolaus Marx;Georg Lübben;Matthias Langenfeld

  • Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease.

    Nikolaus Marx;Johannes Froehlich;Laila Siam;Jochen Ittner

Frequent Co-Authors

Michael Becker
Michael Becker University of Chicago
Julio Rosenstock
Julio Rosenstock The University of Texas Southwestern Medical Center
Peter J. Grant
Peter J. Grant University of Leeds
Joachim Jankowski
Joachim Jankowski RWTH Aachen University
Jürgen Floege
Jürgen Floege RWTH Aachen University
Darren K. McGuire
Darren K. McGuire The University of Texas Southwestern Medical Center
Bernard Zinman
Bernard Zinman University of Toronto
Christoph Wanner
Christoph Wanner University of Würzburg
Massimo Federici
Massimo Federici University of Rome Tor Vergata
Francesco Cosentino
Francesco Cosentino Karolinska University Hospital

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative healthcare degrees online can be a smart move for students interested in medicine, nursing, or advancing within the healthcare field. Many choose online pathways for improved flexibility, lower costs, and the ability to work while studying.

For those wanting to move into advanced practice, online nursing PhD programs offer a way to access doctoral-level education, often at more affordable rates compared to traditional campuses. If you're taking your first step as a working nurse, consider the average cost of RN to BSN programs before enrolling, as costs can vary by school and state.

Prospective students without a nursing background have opportunities as well. Innovative online direct entry MSN programs allow non-nurses to earn a master’s degree and enter nursing in a relatively short timeframe.

For a quicker entry into healthcare careers, ADN programs are a practical and accessible option, helping students become registered nurses in as little as two years. Each online pathway has its own requirements, demand, and opportunities, so it’s crucial to research carefully according to your education goals and career aspirations.

Best Scientists Citing Nikolaus Marx

Trending Scientists

Recently Published Articles